1 Synthesis and molecular docking studies of some novel Schiff bases incorporating 6-butylquinolinedione moiety as potential topoisomerase IIβ inhibitors.

2 synthesis, crystal structure, stacking effect and antibacterial studies of a novel quaternary copper (ii) complex with quinolone

3 1,2,4-Triazole-quinoline/quinolone hybrids as potential anti-bacterial agents.

4 Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

5 Prevalence of quinolone-resistant uropathogenic Escherichia coli in a tertiary care hospital in south Iran

6 Quinolone resistance mechanisms among third-generation cephalosporin resistant isolates of Enterobacter spp. in a Bulgarian university hospital

7 Investigation of six plasmid-mediated quinolone resistance genes among clinical isolates of pseudomonas: a genotypic study in Saudi Arabia

8 Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones

9 Inhibitory effects of fluoroquinolone antibiotics on Babesia divergens and Babesia microti, blood parasites of veterinary and zoonotic importance

10 Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant Moraxella catarrhalis strains isolated in Poland

11 The prevalence of plasmid-mediated quinolone resistance and ESBL-production in Enterobacteriaceae isolated from urinary tract infections

12 Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates

13 Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

14 Mutations in the gyrA, parC, and mexR genes provide functional insights into the fluoroquinolone-resistant Pseudomonas aeruginosa isolated in Vietnam

15 Overview of the development of quinolone resistance in Salmonella species in China, 2005–2016

16 National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

17 Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis

18 Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

19 Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

20 Prevalence of quinolone-resistant uropathogenic Escherichia coli in a tertiary care hospital in south Iran

21 Quinolone resistance mechanisms among third-generation cephalosporin resistant isolates of Enterobacter spp. in a Bulgarian university hospital

22 Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

23 Prevalence of quinolone-resistant uropathogenic Escherichia coli in a tertiary care hospital in south Iran

24 Quinolone resistance mechanisms among third-generation cephalosporin resistant isolates of Enterobacter spp. in a Bulgarian university hospital

25 Investigation of six plasmid-mediated quinolone resistance genes among clinical isolates of pseudomonas: a genotypic study in Saudi Arabia

26 Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones

27 Inhibitory effects of fluoroquinolone antibiotics on Babesia divergens and Babesia microti, blood parasites of veterinary and zoonotic importance

28 Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant Moraxella catarrhalis strains isolated in Poland

29 The prevalence of plasmid-mediated quinolone resistance and ESBL-production in Enterobacteriaceae isolated from urinary tract infections

30 Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates

31 Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

32 Mutations in the gyrA, parC, and mexR genes provide functional insights into the fluoroquinolone-resistant Pseudomonas aeruginosa isolated in Vietnam

33 Overview of the development of quinolone resistance in Salmonella species in China, 2005–2016

34 National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

35 Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis

36 Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

37 Synthesis, in vitro Cytotoxicity and Trypanocidal Evaluation of Novel 1,3,6-Substituted Non-fluoroquinolones

38 Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.

39 Removal of aqueous fluoroquinolones with multi-functional activated carbon (MFAC) derived from recycled long-root Eichhornia crassipes: batch and column studies.

40 The occurrence of sulfonamide and quinolone resistance genes at the Fildes Peninsula in Antarctica.

41 Prevalence and Characterization of Fluoroquinolone Resistant Isolated From an Integrated Broiler Chicken Supply Chain.

42 Rapid and simultaneous determination of three fluoroquinolones in animal-derived foods using excitation-emission matrix fluorescence coupled with second-order calibration method

43 Fluoroquinolone-Resistant Salmonella enterica, Campylobacter spp., and Arcobacter butzleri from Local and Imported Poultry Meat in Kumasi, Ghana

44 Two new quinolone alkaloids from the nearly ripe fruits of .

45 Erratum: Designed Small-Molecule Inhibitors of the Anthranilyl-CoA Synthetase PqsA Block Quinolone Biosynthesis in Pseudomonas aeruginosa (ACS Chemical Biology (2016) 11:11 (3061?3067) DOI: 10.1021/acschembio.6b00575)

46 Prevalence, sequence type, and quinolone resistance of Neisseria lactamica carried in children younger than 15 years in Shanghai, China.

47 SYNTHESIS AND ANTIMICROBIAL ACTIVITIES OF NEW 1,2,4- TRIAZOLES, MANNICH BASES, CONAZOLES, AND FLUOROQUINOLONES

48 A new class of dihaloquinolones bearing N'-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-amino ester precursors: synthesis and antimicrobial activity

49 Sequencing [4+1]-Cycloaddition and Aza-Michael Addition Reactions: A Diastereoselective Cascade for the Rapid Access of Pyrido[2',1':2,3]/Thiazolo[2',3':2,3]imidazo[1,5-a]quinolone Scaffolds as Potential Antibacterial and Anticancer Motifs.

50 Recent advances in the synthetic and medicinal perspective of quinolones: A review.

51 Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities

52 Evidence for stepwise excited state double proton transfer process in quinolone–pyrazole triggered by methanol solvent

53 A nanofiber mat prepared from sulfonated polyaniline for solid-phase extraction of fluoroquinolones from water and biological fluids prior to their quantitation by UPLC-MS/MS.

54 Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.

55 Rate constants of hydroxyl radicals reaction with different dissociation species of fluoroquinolones and sulfonamides: Combined experimental and QSAR studies

56 Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens: a Markov model.

57 Molecular characteristics, antimicrobial resistance profiles, and antibiotic resistance determinants in uropathogenic fluoroquinolone resistant-Escherichia coli isolates

58 Quinolone-isoniazid hybrids: synthesis and preliminary cytotoxicity and anti-tuberculosis evaluation.

59 The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.

60 Facile preparation of magnetic graphene oxide/nanoscale zerovalent iron adsorbent for magnetic solid-phase extraction of ultra-trace quinolones in milk samples.

61 Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative.

62 Interaction of the fluoroquinolone antibiotic, ofloxacin, with titanium oxide nanoparticles in water: Adsorption and breakdown

63 Use of Quinolones for the Treatment of Patients with Bacteremia

64 Long-Term Use of Quinolones and Their Safety

65 Laboratory Survey of Fluoroquinolone Activity

66 Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France

67 New Quinolones: In Vitro Effects as a Potential Source of Clinical Toxicity

68 Use of Quinolones in Chlamydial Infection

69 Susceptibility of Antimicrobial-Resistant Urinary Escherichia coli Isolates to Fluoroquinolones and Nitrofurantoin

70 Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!

71 Pharmacokinetics and Clinical Results of Parenterally Administered New Quinolones in Humans

72 In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli

73 Use of the New Quinolones in Cystic Fibrosis

74 Mode of Action of the Quinolone Antimicrobial Agents: Review of Recent Information

75 Synergy of Fluoroquinolones with Other Antimicrobial Agents

76 Impact of Fluoroquinolones on the Gastrointestinal Flora

77 Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

78 Use of Quinolones in Urinary Tract Infections and Prostatitis

79 The New Quinolones: Back to the Future

80 Quinolone Therapy for Infections of the Central Nervous System

81 Drug Interactions with Quinolones

82 Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital

83 Results of Treatment with Quinolones of Sexually Transmitted Diseases in the Far East: A Brief Summary

84 Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis

85 Use of Quinolones for the Treatment of Osteomyelitis and Septic Arthritis

86 Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades

87 Quinolones in the Treatment of Lower Respiratory Tract Infections

88 Factors influencing fluoroquinolone resistance

89 Use of Quinolones in Pediatric Patients

90 Pharmacokinetics of Fluorinated 4-Quinolones in the Aged

91 Use of Quinolones in Chlamydial Infection

92 Prevention of Infections in Granulocytopenic Patients by Fluorinated Quinolones

93 Bacterial Resistance to Quinolones: Mechanisms and Clinical Importance

94 Quinolones in the Treatment of Salmonella Carriers

95 Application of fluoroquinolone pharmacodynamics

96 Evaluation of a successful fluoroquinolone restriction intervention among high-risk patients: A mixed-methods study

97 Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network

98 Tissue Penetration of the New Quinolones in Humans

99 Quinolone Uptake by Bacteria and Bacterial Killing

100 Surgical Prophylaxis and Treatment of Surgical Infections with Quinolones

101 Antibiotics in the Management of Shigellosis in Children: What Role for the Quinolones?

Keyword Connections

Journals

Research Groups

Bibliographies